{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:42:03Z","timestamp":1649205723206},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.leukres.2011.03.026","type":"journal-article","created":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T01:26:57Z","timestamp":1305077217000},"page":"985-986","source":"Crossref","is-referenced-by-count":0,"title":["An inexpensive way to treat elderly patients with high-risk MDS or AML"],"prefix":"10.1016","volume":"35","author":[{"given":"Andrea","family":"Kuendgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.03.026_bib0050","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","article-title":"Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C","volume":"35","author":"Corsetti","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.03.026_bib0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.03.026_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01703109","article-title":"The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study","volume":"65","author":"Miller","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2011.03.026_bib0020","series-title":"ASH annual meeting abstracts, vol. 114","first-page":"1755","article-title":"Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen","author":"Mufti","year":"2009"},{"key":"10.1016\/j.leukres.2011.03.026_bib0025","series-title":"ASH Annual Meeting Abstracts","first-page":"439","article-title":"Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS","author":"Itzykson","year":"2010"},{"key":"10.1016\/j.leukres.2011.03.026_bib0030","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.03.026_bib0035","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.03.026_bib0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2011.03.026_bib0005","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"D\u00f6hner","year":"2005","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T21:52:23Z","timestamp":1543787543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0145212611001627"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.03.026","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}